Fierce 15 winner Maze Therapeutics just added $190 million to its fundraising pile in time to help its lead candidate, MZE001, make a clinical debut. Maze wrapped up the fundraising round on Monday.
What is driving interest in Maze Therapeutics right now? Maze Therapeutics (MAZE) has drawn fresh attention after recent trading, with the stock closing at $46.01 and showing mixed short term moves, ...
After Maze Therapeutics opted not to participate in the National Advertising Division’s (NAD’s) self-regulatory process for monitoring promotional claims, a case brought by competitor Vertex ...
Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a phase 2 trial. The Bay Area-based biotech unveiled its ambition earlier ...
As if the Upside Down wasn't a terrifying maze in itself, someone has created one in our world. A colossal maze inspired by Netflix favorite Stranger Things has been unveiled in Lafayette, Indiana, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results